Loading news...
Glaukos Corporation (NYSE: GKOS - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the sixteen brokerages that are currently covering the stock, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation, twelve have issued a buy recommendation and one has
Glaukos (GKOS) reported earnings 30 days ago. What's next for the stock?
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, announced today the commercial availability of Epioxa™ HD / Epioxa™ (“Epioxa”), a groundbreaking advancement in corneal cross-linking for the treatment of keratoconus, a rare, sight-threatening corneal disease that is currently far too often undiagnosed and untreated.
Capital International Investors raised its stake in Glaukos Corporation (NYSE: GKOS) by 107.5% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 511,510 shares of the medical instruments supplier's stock after acquiring an additional 264,971 shares during the period. Capital International Investors
Citigroup Inc. lessened its holdings in shares of Glaukos Corporation (NYSE: GKOS) by 61.3% in the third quarter, according to its most recent filing with the SEC. The firm owned 21,912 shares of the medical instruments supplier's stock after selling 34,689 shares during the period. Citigroup Inc.'s holdings in Glaukos were worth $1,787,000
Glaukos Corporation (NYSE: GKOS - Get Free Report) Director Aimee Weisner sold 15,000 shares of the company's stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $117.38, for a total value of $1,760,700.00. Following the completion of the sale, the director owned 18,806 shares in the company, valued
GKOS posts 36% Q4 revenue jump, raises 2026 sales outlook to $600-$620M as iDose TR and Epioxa fuel growth despite wider loss.
Glaukos Corp (NYSE: GKOS) reported mixed results for the fourth quarter on Tuesday.
Glaukos Corporation (GKOS) Q4 2025 Earnings Call Transcript
While the top- and bottom-line numbers for Glaukos (GKOS) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Glaukos (GKOS) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to a loss of $0.4 per share a year ago.
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced financial results for the fourth quarter and full year ended December 31, 2025. Key highlights include: Record net sales of $143.1 million in Q4 2025 increased 36% year-over-year on a reported basis and 34% year-over-year on a constant currency basis.
Glaukos (NYSE: GKOS - Get Free Report) and Inogen (NASDAQ: INGN - Get Free Report) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, earnings, dividends, profitability and risk. Valuation and Earnings This table compares Glaukos and Inogen"s revenue,
Glaukos (GKOS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Principal Financial Group Inc. cut its holdings in Glaukos Corporation (NYSE: GKOS) by 2.2% in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 277,202 shares of the medical instruments supplier's stock after selling 6,188 shares during the period. Principal Financial
Class A shares of the Alger Weatherbie Specialized Growth Fund outperformed the Russell 2500 Growth Index during the fourth quarter of 2025. Natera, Inc., ACADIA Pharmaceuticals Inc., and Glaukos Corp were among the top contributors to performance. FirstService Corp, AAR CORP., and Kratos Defense & Security Solutions, Inc. were among the top detractors from performance.
15,000 shares were exercised as options and immediately sold in the open market for a total of ~$1.9 million at around $127.71 per share on Jan. 22, 2026. This transaction represented 28.60% of Stapley's direct holdings, reducing his direct stake from 52,449 to 37,449 shares, with post-trade direct holdings valued at ~$4.7 million.
From a sector perspective, strength within Industrials and Information Technology offset relative weakness in Health Care. The October earnings report reinforced confidence in Comfort Systems' ability to convert a strong backlog and increasingly sophisticated project mix into sustained earnings growth. We did not make any adjustments to the position and continue to believe that the market opportunity remains robust.
GKOS is positioned for growth as interventional glaucoma adoption expands, iDose and iStent synergies build, and scale drives operating leverage despite margin pressures.
Shares of Glaukos Corporation (NYSE: GKOS - Get Free Report) were up 6% on Wednesday after BTIG Research raised their price target on the stock from $123.00 to $131.00. BTIG Research currently has a buy rating on the stock. Glaukos traded as high as $128.84 and last traded at $125.8350. Approximately 274,089 shares were traded during